A phase 2 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 vaccine based on adeno-associated virus.
نویسندگان
چکیده
The recombinant vaccine, tgAAC09, based on an adeno-associated virus serotype 2 (AAV2) vector encoding HIV-1 subtype C Gag, protease, and part of reverse transcriptase, induced robust T cell and antibody responses in nonhuman primates. In a previous phase I study in 80 healthy HIV-seronegative European and Indian adults, the vaccine was generally safe, well tolerated, and modestly immunogenic when administered once at doses up to 3 x 10(11) DRP. This phase II double-blind, randomized, placebo-controlled trial tested two administrations and a higher dosage of tgAAC009. Ninety-one healthy HIV-seronegative adults from three African countries were given one of three dosage levels of tgAAC09 (3 x 10(10), 3 x 10(11), or 3 x 10(12) DRP) intramuscularly, either at a 6- or 12-month interval; follow-up was 18 months. Overall, 65% and 57% of vaccine recipients experienced local and systemic signs and symptoms, respectively, most being mild. Frequency and severity were not dose related and were similar to those in placebo recipients. No vaccine-related serious adverse events were reported. Overall, HIV-specific T cell responses were detected by IFN-gamma ELISPOT in 17/69 (25%) vaccine recipients with 38% (10/26) responders in the highest dosage group. The response rate improved significantly with boosting at 6, but not 12 months, in the 3 x 10(11) and 3 x 10(12) dosage groups only. Neutralizing antibody titers to the AAV2 did not alter the frequency of immune responses to HIV. Two doses of tgAAC09 were well tolerated at the dosage levels given. Fewer than half the recipients of the highest vaccine dosage, 3 x 10(12) DRP, had T cell responses to HIV.
منابع مشابه
Safety & immunogenicity of tgAAC09, a recombinant adeno-associated virus type 2 HIV-1 subtype C vaccine in India.
BACKGROUND & OBJECTIVES A phase 1 trial of adeno-associated virus based HIV-1 subtype C vaccine (tgAAC09) was conducted at two sites in Germany and Belgium and one site in India. This paper reports the safety and immunogenicity of tgAAC09 in healthy adult Indian volunteers. METHODS Between January 2005 and December 2006, 30 consenting volunteers were enrolled in the placebo controlled double-...
متن کاملDengue virus type-3 envelope protein domain III; expression and immunogenicity
Objective(s): Production of a recombinant and immunogenic antigen using dengue virus type-3 envelope protein is a key point in dengue vaccine development and diagnostic researches. The goals of this study were providing a recombinant protein from dengue virus type-3 envelope protein and evaluation of its immunogenicity in mice. Materials and Methods: Multiple amino acid sequences of different i...
متن کاملImmunogenicity of Concentrated and Purified Inactivated Avian Influenza Vaccine Formulation
Avian influenza (AI) H9N2 is a low pathogenic virus subtype belonging to Orthomyxoviridae family. Given the prevalence of this subtype as an infectious agent in poultry industry, special attention has been always directed toward the development of vaccine production against this infection. The vaccine of this infection is produced by killing the virus and using a mixture of inactivated antigen ...
متن کاملInduction of Immune Response in Animal Model Using Recombinant Anti-NDV Vaccine
Background: Newcastle disease is a major avian disease that causes enormous economic loss in poultry industry. There have been a number of reports on the suitability of plant-based recombinant vaccine against this disease. Fusion (F) and hemagglutinin-neuraminidase (HN) epitopes of the Newcastle disease virus (NDV) represent the major immunogenic sites for development of recomb...
متن کاملImmunogenicity of BHK-Rabies Vaccine in Cattle
In this study, the immunogenicity of a rabies vaccine that was used in one of the Isfahan cattle farms is reported. This vaccine was produced by replication of the Pasteur virus (PV) strain on BHK-21 monolayer cell culture. The virus suspension was inactivated by ß-propiolactone treatment and the harvested pool showed sterility and safety. Thus, the obtained vaccine was tested on mice and a sat...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- AIDS research and human retroviruses
دوره 26 8 شماره
صفحات -
تاریخ انتشار 2010